We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Grin and Bayer it

23 March 2006 By Nina Koeppen

The German conglomerate is acting as Schering’s white knight. Its bid of E86 per share trounces Merck’s hostile offer of E77. Merck will be hard pressed to beat this offer. Bayer has greater synergies with Schering than Merck does.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)